WCA
ALNY icon

Westover Capital Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Westover Capital Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-8,536
Closed -$579K – 97
2016
Q3 		$579K Buy
+8,536
New +$602K 0.43% 63

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Westover Capital Advisors's ALNY Position: Q4 2016 in Review

Westover Capital Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2016, closing a stake of 8,536 shares — an estimated $579K sold.

Westover Capital Advisors first reported a position in ALNY in Q3 2016 and held it in 1 quarter. The position peaked at $579K in Q3 2016. 210 funds tracked by Wall St. Rank hold ALNY as of Q4 2016.

  • Westover Capital Advisors reported no remaining Alnylam Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Westover Capital Advisors sold 8,536 Alnylam Pharmaceuticals shares in Q4 2016, an estimated $579K.
  • Westover Capital Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • Westover Capital Advisors's Alnylam Pharmaceuticals position peaked at $579K in Q3 2016.
  • 210 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2016.

Based on Westover Capital Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.